These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26704203)

  • 21. Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson's disease - the INfusion VErsus STimulation (INVEST) study.
    van Poppelen D; Sisodia V; de Haan RJ; Dijkgraaf MGW; Schuurman PR; Geurtsen GJ; Berk AEM; de Bie RMA; Dijk JM
    BMC Neurol; 2020 Jan; 20(1):40. PubMed ID: 32005175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan.
    Shimbo T; Hira K; Takemura M; Fukui T
    Pharmacoeconomics; 2001; 19(8):875-86. PubMed ID: 11596839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
    Valldeoriola F; Puig-Junoy J; Puig-Peiró R;
    J Med Econ; 2013; 16(2):191-201. PubMed ID: 23035627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subthalamic Nucleus Deep Brain Stimulation May Reduce Medication Costs in Early Stage Parkinson's Disease.
    Hacker ML; Currie AD; Molinari AL; Turchan M; Millan SM; Heusinkveld LE; Roach J; Konrad PE; Davis TL; Neimat JS; Phibbs FT; Hedera P; Byrne DW; Charles D
    J Parkinsons Dis; 2016; 6(1):125-31. PubMed ID: 26967937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deep brain stimulation for Alzheimer disease: a decision and cost-effectiveness analysis.
    Mirsaeedi-Farahani K; Halpern CH; Baltuch GH; Wolk DA; Stein SC
    J Neurol; 2015 May; 262(5):1191-7. PubMed ID: 25740662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deep Brain Stimulation for Advanced Parkinson Disease in Developing Countries: A Cost-Effectiveness Study From China.
    Guo X; Feng C; Pu J; Jiang H; Zhu Z; Zheng Z; Zhang J; Chen G; Zhu J; Wu H
    Neurosurgery; 2023 Apr; 92(4):812-819. PubMed ID: 36729808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost Effectiveness of Deep Brain Stimulation for Parkinson's Disease: A Systematic Review.
    Sasidharan A; Bagepally BS; Kumar SS
    Appl Health Econ Health Policy; 2024 Mar; 22(2):181-192. PubMed ID: 38015368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany.
    Meissner W; Schreiter D; Volkmann J; Trottenberg T; Schneider GH; Sturm V; Deuschl G; Kupsch A
    J Neurol; 2005 Feb; 252(2):218-23. PubMed ID: 15729530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease.
    Liu Y; Li W; Tan C; Liu X; Wang X; Gui Y; Qin L; Deng F; Hu C; Chen L
    J Neurosurg; 2014 Sep; 121(3):709-18. PubMed ID: 24905564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis.
    Stephen JH; Halpern CH; Barrios CJ; Balmuri U; Pisapia JM; Wolf JA; Kampman KM; Baltuch GH; Caplan AL; Stein SC
    Addiction; 2012 Mar; 107(3):624-34. PubMed ID: 21919988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reoperation for suboptimal outcomes after deep brain stimulation surgery.
    Ellis TM; Foote KD; Fernandez HH; Sudhyadhom A; Rodriguez RL; Zeilman P; Jacobson CE; Okun MS
    Neurosurgery; 2008 Oct; 63(4):754-60; discussion 760-1. PubMed ID: 18981887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is improvement in the quality of life after subthalamic nucleus stimulation in Parkinson's disease predictable?
    Daniels C; Krack P; Volkmann J; Raethjen J; Pinsker MO; Kloss M; Tronnier V; Schnitzler A; Wojtecki L; Bötzel K; Danek A; Hilker R; Sturm V; Kupsch A; Karner E; Deuschl G; Witt K
    Mov Disord; 2011 Dec; 26(14):2516-21. PubMed ID: 22170276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness Analysis of Long-Term Intermittent Self-Catheterization with Hydrophilic-Coated and Uncoated Catheters in Patients with Spinal Cord Injury in Japan.
    Watanabe T; Yamamoto S; Gotoh M; Saitoh T; Yokoyama O; Murata T; Takeda M
    Low Urin Tract Symptoms; 2017 Sep; 9(3):142-150. PubMed ID: 28868661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study.
    Witt K; Daniels C; Reiff J; Krack P; Volkmann J; Pinsker MO; Krause M; Tronnier V; Kloss M; Schnitzler A; Wojtecki L; Bötzel K; Danek A; Hilker R; Sturm V; Kupsch A; Karner E; Deuschl G
    Lancet Neurol; 2008 Jul; 7(7):605-14. PubMed ID: 18538636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parkinson's disease patients with subthalamic stimulation and carers judge quality of life differently.
    Lewis CJ; Maier F; Eggers C; Pelzer EA; Maarouf M; Moro E; Zurowski M; Kuhn J; Woopen C; Timmermann L
    Parkinsonism Relat Disord; 2014 May; 20(5):514-9. PubMed ID: 24637125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropsychological effects of deep brain stimulation in subjects with early stage Parkinson's disease in a randomized clinical trial.
    Tramontana MG; Molinari AL; Konrad PE; Davis TL; Wylie SA; Neimat JS; May AT; Phibbs FT; Hedera P; Gill CE; Salomon RM; Wang L; Song Y; Charles D
    J Parkinsons Dis; 2015; 5(1):151-63. PubMed ID: 25613351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression.
    Kabotyanski KE; Najera RA; Banks GP; Sharma H; Provenza NR; Hayden BY; Mathew SJ; Sheth SA
    Transl Psychiatry; 2024 Jun; 14(1):243. PubMed ID: 38849334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Varying time-course of effects of high frequency stimulation of sub-regions of the globus pallidus in patients with parkinson's disease.
    Angeli A; Akram H; Zacharia A; Limousin P; Hariz M; Zrinzo L; Foltynie T
    Parkinsonism Relat Disord; 2015 Jun; 21(6):597-602. PubMed ID: 25842261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.